The finding points to a potential new treatment option for the most common subtype of breast cancer, which accounts for roughly 70% of all cases and is most often diagnosed at Stage 1, 2 or 3.
The finding points to a potential new treatment option for the most common subtype of breast cancer, which accounts for roughly 70% of all cases and is most often diagnosed at Stage 1, 2 or 3.